Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Up 10.7% in December

Celldex Therapeutics, Inc. (NASDAQ:CLDX) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,090,000 shares, an increase of 10.7% from the December 15th total of 7,310,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the days-to-cover ratio is currently 8.0 days.

Celldex Therapeutics Stock Up 4.5 %

Celldex Therapeutics stock traded up $1.02 during midday trading on Friday, hitting $23.78. 854,667 shares of the company’s stock were exchanged, compared to its average volume of 852,336. The firm has a 50-day moving average of $25.80 and a two-hundred day moving average of $31.87. Celldex Therapeutics has a 12 month low of $22.17 and a 12 month high of $53.18.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci acquired 11,500 shares of Celldex Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average cost of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 3.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds have recently modified their holdings of the business. KBC Group NV increased its holdings in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 495 shares during the period. AQR Capital Management LLC boosted its position in Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 1,504 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $76,000. Teachers Retirement System of The State of Kentucky raised its position in shares of Celldex Therapeutics by 5.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after acquiring an additional 2,070 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in shares of Celldex Therapeutics by 23.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock worth $469,000 after purchasing an additional 2,600 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CLDX shares. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Thursday, January 2nd. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target on the stock. Finally, Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.